KFAS
BEAM icon

Keating Financial Advisory Services’s Beam Therapeutics BEAM Stock Holding History

Keating Financial Advisory Services’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206 Hold
6
– – ﹤0.01% 2428
2026
Q1 		$143 Sell
6
-11
-65% -$305 ﹤0.01% 2389
2025
Q4 		$471 Buy
+17
New +$434 ﹤0.01% 1957

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Keating Financial Advisory Services's BEAM Position: Q2 2026 in Review

Keating Financial Advisory Services held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 6 shares worth $206. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

Keating Financial Advisory Services first reported a position in BEAM in Q4 2025 and has held it in 3 quarters since. The position peaked at $471 in Q4 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Keating Financial Advisory Services held 6 shares of Beam Therapeutics worth $206 as of Q2 2026.
  • Keating Financial Advisory Services left its Beam Therapeutics share count unchanged in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2428 holding.
  • Keating Financial Advisory Services first reported a position in Beam Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Beam Therapeutics position peaked at $471 in Q4 2025.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.